BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31588824)

  • 1. How to Pick Out the "Unreal" Gleason 3 + 3 Patients: A Nomogram for More Precise Active Surveillance Protocol in Low-Risk Prostate Cancer in a Chinese Population.
    Qi F; Zhu K; Cheng Y; Hua L; Cheng G
    J Invest Surg; 2021 Jun; 34(6):583-589. PubMed ID: 31588824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
    Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
    Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation.
    He B; Chen R; Gao X; Ren S; Yang B; Hou J; Wang L; Yang Q; Zhou T; Zhao L; Xu C; Sun Y
    Oncotarget; 2016 Mar; 7(13):17275-85. PubMed ID: 26943768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A
    Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
    Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
    Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
    Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
    BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can a nomogram predict apical prostate cancer pathology upgrade from fusion biopsy to final pathology? A multicenter study.
    Feng T; Liang Z; Xiao Y; Pan B; Zhou Y; Ma C; Zhou Z; Yan W; Zhu M
    Cancer Med; 2024 Jun; 13(11):e7341. PubMed ID: 38845479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of a nomogram incorporating cribriform morphology for the prediction of adverse pathology in prostate cancer at radical prostatectomy.
    Wang B; Gao J; Zhang Q; Fu Y; Liu G; Zhang C; Wei W; Huang H; Shi J; Li D; Guo H
    Oncol Lett; 2020 Sep; 20(3):2797-2805. PubMed ID: 32782597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel nomogram for the prediction of seminal vesicle invasion including multiparametric magnetic resonance imaging.
    Martini A; Gupta A; Cumarasamy S; Lewis SC; Haines KG; Briganti A; Montorsi F; Tewari AK
    Int J Urol; 2019 Apr; 26(4):458-464. PubMed ID: 30659663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation.
    Wang X; Zhang Y; Zhang F; Ji Z; Yang P; Tian Y
    BMC Urol; 2021 Jan; 21(1):3. PubMed ID: 33407381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
    Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
    Blute ML; Shiau JM; Truong M; Shi F; Abel EJ; Downs TM; Jarrard DF
    World J Urol; 2017 May; 35(5):729-735. PubMed ID: 27631325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging.
    Di Trapani E; Luzzago S; Peveri G; Catellani M; Ferro M; Cordima G; Mistretta FA; Bianchi R; Cozzi G; Alessi S; Matei DV; Bagnardi V; Petralia G; Musi G; De Cobelli O
    Urol Oncol; 2021 Jul; 39(7):431.e15-431.e22. PubMed ID: 33423938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomogram Predicting Adverse Pathology Outcome on Radical Prostatectomy in Low-Risk Prostate Cancer Men.
    Nasri J; Barthe F; Parekh S; Ratnani P; Pedraza AM; Wagaskar VG; Olivier J; Villers A; Tewari A
    Urology; 2022 Aug; 166():189-195. PubMed ID: 35263642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
    Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
    Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically significant Gleason sum upgrade: external validation and head-to-head comparison of the existing nomograms.
    Iremashvili V; Manoharan M; Pelaez L; Rosenberg DL; Soloway MS
    Cancer; 2012 Jan; 118(2):378-85. PubMed ID: 21732339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy.
    Kim TH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    Scand J Urol; 2017 Feb; 51(1):27-32. PubMed ID: 28168924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.